1516896-06-2

Basic information

• Product Name: Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl-
• Synonyms: Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl-;SEP-0371845
• CAS NO: 1516896-06-2
• Molecular Formula: C21H19N7
• Molecular Weight: 369.42246
• Mol File: 1516896-06-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.52±0.1 g/cm3(Predicted)
• PKA: 5.38±0.50(Predicted)
• CAS DataBase Reference: Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl-(1516896-06-2)
• EPA Substance Registry System: Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl-(1516896-06-2)

Safety Data

• Hazardous Substances Data: 1516896-06-2(Hazardous Substances Data)

Upstream product

• 13949-93-4 (+/-)-ethyl trans-2-formyl-1-cyclopropanecarboxylate 
• 1351515-90-6 1-amino-3,6-dimethylpyrazin-2(1H)-iminium 2,4,6-trimethylbenzenesulfonate 
• 1516895-53-6 trans-2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl)-3-methylimidazo[2,1-f][1,6]naphthyridine 
• 1351516-77-2 5-azido-1,6-naphthyridine 
• 23616-31-1 1,6-naphthyridine-5(6H)-one 
• 23616-32-2 5-chloro-[1,6]naphthyridine 
• 55570-60-0 1,6-naphthyridin-5-amine 

Relevant articles and documents

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.